Almonertinib(HS-10296)在经治EGFR突变晚期NSCLC中的安全性、疗效与药代动力学:多中心开放标签Ⅰ期试验
该Ⅰ期开放标签多中心试验评估了第三代EGFR TKI Almonertinib(HS-10296)在既往EGFR TKI治疗后进展的EGFR突变阳性局部晚期或转移性NSCLC患者中的安全性、疗效和药代动力学。研究纳入120例患者,剂量递增阶段未确定最大耐受剂量,260 mg方案因安全性和暴露饱和未进一步评估。在94例EGFR T790M突变患者中,研究者评估的客观缓解率为52%(95%CI 42-63),疾病控制率为92%(95%CI 84-96),中位无进展生存期为11.0个月(95%CI 9.5-未达到)。结论认为Almonertinib对EGFR T790M突变且既往接受过EGFR TKI治疗的患者安全、可耐受且有效。
要点
- 在EGFR T790M突变经治患者中,Almonertinib客观缓解率达52%,疾病控制率达92%。
- 中位无进展生存期为11.0个月(95%CI 9.5-未达到)。
- 常见≥3级治疗相关不良事件为血肌酸磷酸激酶升高(10%)和丙氨酸氨基转移酶升高(3%)。
核心结论
- Almonertinib对既往EGFR TKI治疗后进展的EGFR T790M突变局部晚期或转移性NSCLC患者安全、可耐受且有效。
研究设计与样本
- 本研究为Ⅰ期、开放标签、多中心临床试验(NCT0298110),包含剂量递增(55、110、220、260 mg)和剂量扩展(55、110、220 mg)队列,每日一次口服给药。
- 共纳入120例患者,其中剂量递增队列26例,剂量扩展队列94例;剂量扩展队列中每例患者均进行肿瘤活检以确定EGFR T790M状态。
主要发现
- 剂量递增阶段未确定最大耐受剂量;260 mg方案因安全性顾虑和暴露饱和未在剂量扩展阶段进一步评估。
- 最常见的≥3级治疗相关不良事件为血肌酸磷酸激酶升高(10%)和丙氨酸氨基转移酶升高(3%)。
- 在94例EGFR T790M突变剂量扩展队列患者中,研究者评估的客观缓解率为52%(95%CI 42-63),疾病控制率为92%(95%CI 84-96)。
- 中位无进展生存期为11.0个月(95%CI 9.5-未达到)。
临床怎么用
- 对于既往EGFR TKI治疗后进展且携带EGFR T790M突变的局部晚期或转移性NSCLC患者,Almonertinib可作为治疗选择。
- 治疗期间需关注血肌酸磷酸激酶升高和丙氨酸氨基转移酶升高等治疗相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Almonertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations. This first-in-human trial aimed to evaluate the safety, efficacy, and pharmacokinetics of almonertinib in patients with locally advanced or metastatic EGFR mutation-positive NSCLC that had progressed after pevious EGFR TKI therapy. METHODS: This phase 1, open-label, multicenter clinical trial (NCT0298110) included dose-escalation (55, 110, 220, and 260 mg) and dose-expansion cohorts (55, 110, and 220 mg) with once daily oral administration of almonertinib. In each expansion cohort, tumor biopsies were obtained for the determination of EGFR T790M status. The safety, tolerability, antitumor activity, and pharmacokinetics of almonertinib were evaluated. RESULTS: A total of 120 patients (26 patients in the dose-escalation cohort and 94 patients in the dose-expansion cohort) were enrolled. The maximum tolerated dose was not defined in the dose-escalation phase; the 260 mg regimen was not further evaluated in the dose-expansion phase owing to safety concerns and saturation of exposure. The most common treatment-related grade greater than or equal to 3 adverse events were increased blood creatine phosphokinase (10%) and increased alanine aminotransferase (3%). Among 94 patients with the EGFR T790M mutation in the dose-expansion cohort, the investigator-assessed objective response rate and disease control rate were 52% (95% confidence interval [CI]: 42-63) and 92% (95% CI: 84-96), respectively. Median progression-free survival was 11.0 months (95% CI: 9.5-not reached) months. CONCLUSIONS: Almonertinib is safe, tolerable and effective for patients with locally advanced or metastatic NSCLC harboring the EGFR T790M mutation who were pretreated with EGFR TKIs.
引用
- Yang JC, Camidge DR, Yang CT, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020. PMID: 32916310. doi:10.1016/j.jtho.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。